Attached files
file | filename |
---|---|
10-Q - FORM 10-Q - Medite Cancer Diagnostics, Inc. | c58278ae10vq.htm |
EX-10.1 - EX-10.1 - Medite Cancer Diagnostics, Inc. | c58278aexv10w1.htm |
EX-31 - EX-31 - Medite Cancer Diagnostics, Inc. | c58278aexv31.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, the undersigned Chief Executive Officer and Chief Financial Officer of CytoCore, Inc.
(the Company) certifies that, to his knowledge:
1. The Companys Form 10-Q for the quarter ended March 31, 2010 (the Report) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
/s/ Robert F. McCullough, Jr. | ||||
Robert F. McCullough, Jr. | ||||
Chief Executive Officer and Chief Financial Officer |
||||
Dated: May 24, 2010 | ||||